Bone osteosarcoma
MONDO:0002629A usually aggressive malignant bone-forming mesenchymal neoplasm arising from the bone. It may arise de novo or from a pre-existing lesion of the bone. Pain and a palpable mass are the most frequent clinical sign and symptom. It may spread to other anatomic sites, particularly the lungs.
Also known as: bone osteosarcoma, osteosarcoma of bone, osteosarcoma, somatic, osteosarcoma, somatic mutation
2795 clinical trials for this condition and its sub-types, 8 tagged with Bone osteosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bone osteosarcoma
-
Conventional osteosarcoma 0 trials
4 sub-types
- Childhood intracortical osteosarcoma 0 trials
- Chondroblastic osteosarcoma 0 trials
- Fibrosarcomatous osteosarcoma 0 trials
- Osteoblastic osteosarcoma 0 trials
-
Peripheral osteosarcoma 0 trials
3 sub-types
- High grade surface osteosarcoma 0 trials
- Juxtacortical osteosarcoma 0 trials Sub-types →
- Periosteal osteogenic sarcoma 0 trials
-
Telangiectatic osteogenic sarcoma 0 trials
Most studied deeper sub-types
-
Could a targeted drug boost chemo for osteosarcoma?
Disease control PausedThis trial is testing whether adding the targeted drug cabozantinib to standard chemotherapy (methotrexate, doxorubicin, and cisplatin) helps people with newly diagnosed osteosarcoma, a type of bone cancer. The study includes over 1,100 participants and aims to see if the combina…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental drug shows promise for Tough-to-Treat bone cancers
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in 90 patients with osteosarcoma or Ewing sarcoma that has come back or spread. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. Researchers are checking whether the canc…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug combo aims to fight Hard-to-Treat sarcomas
Disease control OngoingThis phase II trial tests two immunotherapy drugs, oleclumab and durvalumab, in 75 people with advanced sarcoma (angiosarcoma, dedifferentiated liposarcoma, or osteosarcoma) that has returned, spread, or stopped responding to treatment. The goal is to see if the combination can s…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Breathing in a cancer fighter: inhaled IL-2 trial targets lung tumors
Disease control OngoingThis study tests an inhaled form of interleukin-2 (IL-2), a protein that boosts the immune system, in people whose cancer has spread to the lungs. The goal is to find the best dose and see if it can shrink lung tumors. About 70 adults with cancers like melanoma, sarcoma, or kidne…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC